| Date Filed | Type | Description |
| 08/18/2023 |
4
| RALLIS CHRIS A (Director) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.|
Txns:
| Sold 673 shares
@ $7.85, valued at
$5.3k
|
|
| 08/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
4
| Haigh Adrian (COO) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.|
Txns:
| Granted 200,000 options
@ $8.03, valued at
$1.6M
|
|
| 08/07/2023 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/04/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/04/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/06/2023 |
4
| RALLIS CHRIS A (Director) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.|
Txns:
| Sold 2,207 shares
@ $8.47, valued at
$18.7k
Exercised 5,208 options to buy
@ $0.96, valued at
$5k
|
|
| 06/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/30/2023 |
4
| Andrade Robert (CFO) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.|
Txns:
| Sold 10,000 shares
@ $8.99, valued at
$89.9k
Sold 7,500 shares
@ $8.97, valued at
$67.3k
Sold 7,500 shares
@ $8.82, valued at
$66.2k
Exercised 25,000 options to buy
@ $2.45, valued at
$61.3k
|
|
| 06/29/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/28/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/06/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/19/2023 |
4
| RALLIS CHRIS A (Director) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.|
Txns:
| Sold 833 shares
@ $7.36, valued at
$6.1k
Sold 925 shares
@ $7.36, valued at
$6.8k
|
|
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/04/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/03/2023 |
4
| Andrade Robert (CFO) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.|
Txns:
| Granted 75,000 options to buy
@ $8.32, valued at
$624k
Granted 37,500 options to buy
@ $0 |
|
| 04/03/2023 |
4
| Raykov Rosty (CEO) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.|
Txns:
| Granted 175,000 options to buy
@ $8.32, valued at
$1.5M
Granted 87,500 options to buy
@ $0 |
|
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| Sonic GP LLC reports a 9.8% stake in Fennec Pharmaceuticals Inc. |
| 01/31/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/25/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 12/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/15/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 12/13/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/01/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/17/2022 |
4
| RALLIS CHRIS A (Director) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.|
Txns:
| Sold 333 shares
@ $7.99, valued at
$2.7k
|
|
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
|